Login
$EQ
$1.23 +$0.08 (6.96%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
Bruce D. Steel Also a director
Chief Executive Officer
59 Not stated Not stated $4,255,248
Christine Zedelmayer
Chief Operating Officer
56 Since 2020
6 years
2018 $2,102,076
Daniel M. Bradbury Also a director
CHAIRMAN
Title from the Form 4 dated May 28, 2026
64 Not stated Not stated Not reported
Stephen Connelly
President and CSO
Title from the Form 4 dated Jun 4, 2026
44 Not stated Not stated $2,701,826
Penny Tom
Principal Accounting Officer
Title from the Form 4 dated May 28, 2026
Not stated Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
4 of 7
stated in the proxy
Average tenure
7.7 years
from year joined
CEO also chairs the board
No
Daniel M. Bradbury
Director Age On board Independent Committees Other public boards 2025 pay Source
Daniel M. Bradbury
64 2017
9 years
Not independent None stated Castle Biosciences, Inc, Biocon Biologics Ltd., Vivani Medical, Inc. $177,289
Bruce D. Steel
59 2017
9 years
Not independent None stated None stated Paid as CEO
Charles McDermott
54 2018
8 years
Independent None stated None stated $61,462
Martha J. Demski
73 2018
8 years
Independent None stated Alpha Teknova Inc. $76,462
Mark Pruzanski
58 2018
8 years
Independent None stated None stated $63,337
Barbara Troupin
58 2022
4 years
Independent
Audit Committee Nominating and Corporate Governance Committee
None stated $63,962
Peter Colabuono
Not stated Not stated Not independent None stated None stated $48,962

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

4 disclosed in the proxy filed Apr 15, 2026
Biocon Limited
former holder of more than 5% of our common stock
$363,000
2025

Termination agreement ending the Biocon Agreements; technical service fee owed to us set off against amounts we owed Biocon

With Equillium Open in proxy
Biocon Limited
$0.4 million
2024

Co-funding of a Phase 2 clinical study of itolizumab in ulcerative colitis conducted by Biocon in India; our share of study costs

With Equillium Open in proxy
Syngene International Limited
wholly-owned subsidiary of Biocon
$5.4 million
July 2023

Work order with Syngene for chemistry, manufacturing and controls services for itolizumab, substantially all paused in Q3 2024

Decheng Capital Management III (Cayman) LLC
beneficial owner of more than 5% of our common stock
$0.5 million

Acquisition of Ariagen under a stock purchase agreement; we assumed Ariagen liabilities and may owe regulatory approval milestones, up to $50.6 million of which would go to Decheng affiliates

With Ariagen Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support